Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review

Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review

Liver cancer remains a global challenge of healthcare, with the incidence growing worldwide. According to various authors, over 1 million patients will be diagnosed with liver cancer each year by 2025. The molecular pathogenesis of HCC varies with respect to genotoxic lesions and aetiologies. Althou...

Full description

Bibliographic Details
Main Authors:	K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. R. Rakhmatullina, I. A. Menshikova, R. R. Abdeev, N. I. Sultanbaeva, E. V. Popova, G. A. Serebrennikov
Format:	Article
Language:	English
Published:	Bashkir State Medical University 2022-07-01
Series:	Креативная хирургия и онкология
Subjects:	hepatocellular carcinoma liver cancer molecular pathogenesis driver mutations tumour microenvironment non-alcoholic steatohepatitis viral hepatitis
Online Access:	https://www.surgonco.ru/jour/article/view/695

Similar Items

Immunotherapy of advanced hepatocellular carcinoma: case report and literature review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Neuroendocrine Tumours: a Literature Review
by: K. V. Menshikov, et al.
Published: (2021-05-01)

Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice
by: G. A. Serebrennikov, et al.
Published: (2023-07-01)

Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
by: Daryl Ramai, et al.
Published: (2021-02-01)

Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma
by: Zelin Tian, et al.
Published: (2022-09-01)

Molecular characterization of plasma virome of hepatocellular carcinoma (HCC) patients
by: Niamat Ullah Khan, et al.
Published: (2024-04-01)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
by: Zuzana Macek Jilkova
Published: (2022-04-01)

LincRNA ZNF529-AS1 inhibits hepatocellular carcinoma via FBXO31 and predicts the prognosis of hepatocellular carcinoma patients
by: Yang Ma, et al.
Published: (2023-02-01)

An update on the role of complement in hepatocellular carcinoma
by: Zhijie Xiao, et al.
Published: (2022-10-01)

CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma
by: Jungang Zhao, et al.
Published: (2022-11-01)

Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma
by: Kunfu Dai, et al.
Published: (2022-05-01)

Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01)

Combined Use of Cabozantinib and Nivolumab in Clinical Practice
by: V. E. Askarov, et al.
Published: (2024-04-01)

Predictors of Multiple Primary Malignancies: Literature Review
by: A. V. Sultanbaev, et al.
Published: (2023-10-01)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
by: Gaoxuan Shao, et al.
Published: (2022-07-01)

CAT and CXCL8 are crucial cofactors for the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma, the immune infiltration and prognosis of hepatocellular carcinoma
by: Liang Yang, et al.
Published: (2025-03-01)

Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma
by: Yu Junjie, et al.
Published: (2023-01-01)

Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth
by: Stéphanie Lacotte, et al.
Published: (2023-12-01)

Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?
by: A.L. Chagas, et al.
Published: (2009-10-01)

Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
by: Rui Li, et al.
Published: (2022-11-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01)

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances
by: Ayana R. Kumar, et al.
Published: (2024-10-01)

Immunotherapy for hepatocellular carcinomaKey points
by: Alexa Childs, et al.
Published: (2024-10-01)

Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma
by: Jun Zou, et al.
Published: (2022-08-01)

Efficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
by: Shih-Chieh Chien, et al.
Published: (2022-10-01)

Metastatic renal cell carcinoma, the possibility of targeted therapy. Case.
by: K. V. Menshikov, et al.
Published: (2021-12-01)

Advances and Challenges in Hepatocellular Carcinoma: A Comprehensive Review
by: Mateusz Dorochowicz, et al.
Published: (2023-12-01)

An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma
by: Wenjuan Wang, et al.
Published: (2023-03-01)

The role of zinc transporter proteins as predictive and prognostic biomarkers of hepatocellular cancer
by: Ceylan V. Bitirim
Published: (2021-10-01)

Experience in treating BRCA-associated breast cancer. The BRCA-history of a family
by: A. V. Sultanbaev, et al.
Published: (2021-08-01)

Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations
by: CM Oneta
Published: (2002-09-01)

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
by: Konstantinos Arvanitakis, et al.
Published: (2022-07-01)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
by: Yu S, et al.
Published: (2022-08-01)

CD206 accelerates hepatocellular carcinoma progression by regulating the tumour immune microenvironment and increasing M2-type polarisation of tumour-associated macrophages and inflammation factor expression
by: Zhiyuan Mao, et al.
Published: (2024-09-01)

Clinical case of the treatment of metastatic luminal breast cancer
by: A. F. Nasretdinov, et al.
Published: (2021-12-01)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
by: Margaret LP Teng, et al.
Published: (2023-04-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)